Vismodegib in locally advanced basal cell carcinoma: Nine-year real-world experience

Affiliations

¹ First Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.
² Specialized Cancer Treatment and Reconstruction Center, General Hospital of Thessaloniki 'George Papanikolaou', Thessaloniki, Greece.
³ Department of Medical Oncology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.
⁴ Second Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.
⁵ Third Department of Cardiology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.
⁶ Department of Radiation Oncology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.
⁷ Third Department of Medical Oncology, Theagenio Cancer Hospital, Thessaloniki, Greece.

Aimilios Lallas et al. J Eur Acad Dermatol Venereol. 2025.

. 2025 Nov 15.

doi: 10.1111/jdv.70194. Online ahead of print.

¹ First Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.
² Specialized Cancer Treatment and Reconstruction Center, General Hospital of Thessaloniki 'George Papanikolaou', Thessaloniki, Greece.
³ Department of Medical Oncology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.
⁴ Second Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.
⁵ Third Department of Cardiology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.
⁶ Department of Radiation Oncology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.
⁷ Third Department of Medical Oncology, Theagenio Cancer Hospital, Thessaloniki, Greece.

No abstract available

Keywords: basal cell carcinoma (BCC); complete response; partial response; recurrence rate; response rate; vismodegib; vismodegib rechallenge.

References

1. Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB, et al. European consensus‐based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023. Eur J Cancer. 2023;192:113254.
1. Sekulic A, Migden MR, Basset‐Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long‐term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:332.
1. Basset‐Séguin N, Hauschild A, Kunstfeld R, Grob JJ, Dréno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open‐label trial. Eur J Cancer. 2017;86:334–348.
1. Ruiz‐Salas V, Podlipnik S, Sandoval‐Clavijo A, Sanmartin‐Jiménez O, Bernia‐Petit E, Bonfill‐Ortí M, et al. Real‐world experience with vismodegib on advanced and multiple BCCs: data from the RELIVIS study. Dermatology. 2023;239(5):685–693.
1. Herms F, Lambert J, Grob JJ, Haudebourg L, Bagot M, Dalac S, et al. Follow‐up of patients with complete remission of locally advanced basal cell carcinoma after vismodegib discontinuation: a multicenter French study of 116 patients. J Clin Oncol. 2019;37(34):3275–3282.